164 related articles for article (PubMed ID: 33961025)
1. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series.
Shneyderman M; Ahlawat S; Christopher-Stine L; Paik JJ
Rheumatology (Oxford); 2021 Nov; 60(11):e387-e388. PubMed ID: 33961025
[No Abstract] [Full Text] [Related]
2. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
Kurtzman DJ; Wright NA; Lin J; Femia AN; Merola JF; Patel M; Vleugels RA
JAMA Dermatol; 2016 Aug; 152(8):944-5. PubMed ID: 27120749
[No Abstract] [Full Text] [Related]
3. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Wendel S; Venhoff N; Frye BC; May AM; Agarwal P; Rizzi M; Voll RE; Thiel J
J Autoimmun; 2019 Jun; 100():131-136. PubMed ID: 30862449
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis.
Sugiura K; Muro Y; Akiyama M
J Am Acad Dermatol; 2012 Oct; 67(4):e167-8. PubMed ID: 22980285
[No Abstract] [Full Text] [Related]
5. Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody.
Gossez M; Levesque M; Khouatra C; Cottin V; Garnier L; Fabien N
Eur Respir Rev; 2015 Jun; 24(136):370-2. PubMed ID: 26028648
[TBL] [Abstract][Full Text] [Related]
6. Anti-NXP2 antibody-associated extensive subcutaneous calcinosis in adult-onset myositis.
Goulabchand R; Guilpain P; Cyteval C; Le Quellec A
Rheumatology (Oxford); 2017 Oct; 56(10):1661. PubMed ID: 28605526
[No Abstract] [Full Text] [Related]
7. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.
Fredi M; Bartoli F; Cavazzana I; Ceribelli A; Carabellese N; Tincani A; Satoh M; Franceschini F
Clin Exp Rheumatol; 2017; 35(2):303-308. PubMed ID: 27908312
[TBL] [Abstract][Full Text] [Related]
8. An Unusual Cause of Dysphagia.
Jerome R; Sebastien H; Nadine MB
Gastroenterology; 2020 May; 158(6):e3-e5. PubMed ID: 31738914
[No Abstract] [Full Text] [Related]
9. Systemic Calcinosis in NXP2-Dermatomyositis.
Martín D; Curbelo J; Moldenhauer F
J Clin Rheumatol; 2019 Jun; 25(4):e35. PubMed ID: 29319550
[No Abstract] [Full Text] [Related]
10. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
Ohmura SI; Yamabe T; Naniwa T
Mod Rheumatol Case Rep; 2021 Jan; 5(1):76-81. PubMed ID: 32867615
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
12. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
13. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series.
Park HS; Kim MW; Lee JS; Yoon HS; Huh CH; Kwon O; Cho S
J Am Acad Dermatol; 2017 Nov; 77(5):978-980. PubMed ID: 29029911
[No Abstract] [Full Text] [Related]
14. FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis.
Nakamura N; Izumi R; Hoshi Y; Takai Y; Ono R; Suzuki N; Nagai T; Ishii Y; Ishii T; Harigae H; Okada S; Aiba S; Okiyama N; Fujimoto M; Kuroda H; Tateyama M; Aoki M
Rheumatology (Oxford); 2019 Oct; 58(10):1888. PubMed ID: 30879053
[No Abstract] [Full Text] [Related]
15. Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy.
Fanouriakis A; Lazarini A; Sofianos I; Papadopoulos C; Bagiazidou E; Balanika A; Elezoglou A
Rheumatology (Oxford); 2021 Nov; 60(11):e378-e380. PubMed ID: 33956080
[No Abstract] [Full Text] [Related]
16. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the Interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib.
Robert M; Gallay L; Garnier L; Pescarmona R; Hot A
Joint Bone Spine; 2023 Jul; 90(4):105532. PubMed ID: 36706944
[No Abstract] [Full Text] [Related]
18. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
Tanaka Y; Takeuchi T; Yamanaka H; Nakamura H; Toyoizumi S; Zwillich S
Mod Rheumatol; 2015 Jul; 25(4):514-21. PubMed ID: 25496464
[TBL] [Abstract][Full Text] [Related]
20. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
